Showing results (31-40 of 67) with videos related to
Sort By:
Pageof 7
International Journal of Molecular Sciences|November 24, 2015
Andrographolide Inhibits Ovariectomy-Induced Bone Loss via the Suppression of RANKL Signaling PathwaysTao Wang, Qian Liu, Lin Zhou, et al.Frontiers in Pharmacology|April 16, 2020
Pregnenolone Inhibits Osteoclast Differentiation and Protects Against Lipopolysaccharide-Induced Inflammatory Bone Destruction and Ovariectomy-Induced Bone LossXiaochen Sun, Chenxi Zhang, Huan Guo, et al.Toxicology Letters|April 25, 2019
Inhibition of Rac1 activity alleviates PM2.5-induced pulmonary inflammation via the AKT signaling pathwayShuijuan Zhang, Weixi Zhang, Xiaolei Zeng, et al.Gland Surgery|August 7, 2025
Identification of high- and low-risk groups for ipsilateral recurrence within 10 years after breast-conserving surgery for ductal carcinoma in situ and personalized treatment: a retrospective studyJichun Zhou, Qingliang Wu, Xixi Lin, et al.Journal of Cellular Physiology|March 1, 2019
Tiliroside is a new potential therapeutic drug for osteoporosis in miceKai Li, Yu Xiao, Ziyi Wang, et al.The Oncologist|October 22, 2025
Omitting radiotherapy in LUMINA-like breast cancer after breast conserving surgery: 10-year results of a population-based cohort studyShenkangle Wang, Ziyu Zhu, Binbin Cui, et al.International Journal of Biological Sciences|April 30, 2025
Conception and Concern: A Review of Breast Cancer Risk in Assisted Reproductive TechnologyZijie Guo, Ziyu Zhu, Xixi Lin, et al.Nanoscale|July 25, 2020
Chitosan derived nitrogen-doped carbon dots suppress osteoclastic osteolysis via downregulating ROSRunfeng Chen, Guanxiong Liu, Xiaochen Sun, et al.Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|December 20, 2015
Dihydroartemisinin, an Anti-Malaria Drug, Suppresses Estrogen Deficiency-Induced Osteoporosis, Osteoclast Formation, and RANKL-Induced Signaling PathwaysLin Zhou, Qian Liu, Mingli Yang, et al.Drug Design, Development and Therapy|January 14, 2021
Pristimerin Protects Against OVX-Mediated Bone Loss by Attenuating Osteoclast Formation and Activity via Inhibition of RANKL-Mediated Activation of NF-κB and ERK Signaling PathwaysXuedong Li, Xixi Lin, Zuoxing Wu, et al.Pageof 7